



## **Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024**

September 2, 2024 at 5:00 PM EDT

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.

### **Conference Call and Webcast Presentation**

Date and Time: Tuesday, September 3, 2024 at 8:00 a.m. ET

Webcast: [LINK](#)

A replay of the presentation will be posted, when available, to Praxis' website on the "[Events and Presentations](#)" page under the investor section of the [website](#).

### **About Praxis**

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit [www.praxismedicines.com](http://www.praxismedicines.com) and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines [investors@praxismedicines.com](mailto:investors@praxismedicines.com) 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com) 617-430-7576